Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer.
Fiche publication
Date publication
août 2024
Journal
The Cochrane database of systematic reviews
Auteurs
Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie
Tous les auteurs :
Orillard E, Adhikari A, Malouf RS, Calais F, Marchal C, Westeel V
Lien Pubmed
Résumé
Lung cancer is a cancer of the elderly, with a median age at diagnosis of 71. More than one-third of people diagnosed with lung cancer are over 75 years old. Immune checkpoint inhibitors (ICIs) are special antibodies that target a pathway in the immune system called the programmed cell death 1/programmed cell death-ligand 1 (PD-1/PD-L1) pathway. These antibodies help the immune system fight cancer cells by blocking signals that cancer cells use to avoid being attacked by the immune system. ICIs have changed the treatment of people with lung cancer. In particular, for people with previously-untreated advanced non-small cell lung cancer (NSCLC), current first-line treatment now comprises ICIs plus platinum-based chemotherapy, rather than platinum-based chemotherapy alone, regardless of their PD-L1 expression status. However, as people age, their immune system changes, becoming less effective in its T cell responses. This raises questions about how well ICIs work in older adults.
Mots clés
Humans, Carcinoma, Non-Small-Cell Lung, drug therapy, Lung Neoplasms, drug therapy, Bevacizumab, therapeutic use, Aged, Randomized Controlled Trials as Topic, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Immune Checkpoint Inhibitors, therapeutic use, Quality of Life, Progression-Free Survival, Platinum Compounds, therapeutic use
Référence
Cochrane Database Syst Rev. 2024 08 13;8(8):CD015495